ARIC MANUSCRIPT PROPOSAL FORM

Manuscript #543B

1. Full Title: Association of Soluble Thrombomodulin Levels with Incident Coronary Heart Disease and Asymptomatic Carotid Atherosclerosis; the ARIC Study

Abbreviated Title: Thrombomodulin and CHD

2. Writing Group:
Lead: Veikko Salomaa
Address: University of North Carolina Cardiovascular Epidemiology NationsBank, Suite 306 137 East Franklin Street Chapel Hill, NC 27514
Phone: (919) 966-4014
Fax: (919) 966-9800
Email: veikko_salomaa@unc.edu

Carmen Mathei Nena Aleksic Leticia Sansores Aaron Folsom Harinder Juneja Lloyd E. Chambless Kenneth K. Wu

3. Timeline:

Soluble thrombomodulin (STM) measurements have been completed. Data analyses can begin as soon as data arrives at Chapel Hill. First draft of the manuscript should be ready during spring 1998.

4. Rationale:

Hemostatic factors play an important role in the pathogenesis of atherothrombotic diseases. In this study we propose to evaluate the association of plasma STM levels with incident coronary heart disease (CHD) and asymptomatic carotid atherosclerosis. Thrombomodulin is an endothelial integral membrane glycoprotein with a major role in the regulation of intravascular coagulation (1-3). It functions as a thrombin receptor and accelerates activation of protein C. Activated protein C in the presence of protein S,inactivates factors VIIIa and Va, thereby inhibiting thrombin formation.

Thrombomodulin also acts as a competetive inhibitor of fibrinogen clotting, inhibits thrombin activation of platelets and blocks thrombin binding to the platelet surface (1). It also accelerates the inactivation of prourokinase, suggesting a regulatory role in the cellular fibrinolytic system. The cell-surface expression of thrombomodulin has been reported to increase in vitro in response to CAMP, retinoic acid and thrombin and decrease in response to endotoxin, hypoxia, interleukin-l, tumor necrosis factor-a and homocysteine (4). Thrombomodulin can also be found in plasma as a soluble form, probably released by leukocyte proteases or activated proteolytic enzymes in the coagulation-fibrinolytic system; the soluble form is considered to be a marker of endothelial cell injury (5-6). Increased levels of antigenic component have been reported in thrombotic thrombocytopenic purpura, disseminated intravascular coagulation, atherosclerosis, connective tissue diseases, pulmonary thromboembolism, acute respiratory distress syndrome, chronic and acute renal failure, acute hepatic failure, thalassemia, diabetic angiopathy (7-9). Few studies have reported plasma thrombomodulin levels in atherosclerosis and ischaemic heart disease (7,8), which gave inconsistent results. In order to attain sufficient power for valid analysis, prospective studies involving large sample size are needed. The ARIC Study is well suited for determining the potential role of plasma levels of thrombomodulin as a risk factor for acute ischaemic events (10). We propose to look at the inter-relations of thrombomodulin with the other hemostatic factors measured at baseline.

5. Main Hypothesis:

The plasma STM levels are associated positively with asymptomatic atherosclerosis and incident CHD, independent of other major risk factors.

6. Data (variables, time window, source, inclusions/exclusions): STM measured by ELISA technique has been completed in 2048 baseline samples (carotid atherosclerosis cases, incident CHD cases and cohort random sample). These will be analysed using the case-cohort design. Persons with prevalent CHD or history of stroke or TIA at baseline will be excluded. Important covariates include age, race, field center, "standard" CVD risk factors, other hemostatic factors, esp. fibrinogen.

REFERENCES:

1. Esmon C. Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface. The FASEB J 1995;9:946 955.

2. Sadler EJ. Thrombomodulin structure and function. Thromb Haemost 1997;78:392-395.

3. Takano S, Kimura S, Ohdama S, Aoki N. Plasma thrombomodulin in health and diseases. Blood 1990;76:2024-2029.

4. Blann A, Taberner D. A reliable marker of endothelial cell dysfunction: does it exist ? Br J Haematol 1995;90:244-248.

5. Seigneur M, DuEourq P, Conri C, Pruvost A, Boisseau M. Plasma thrombomodulin: new approach of endothelium damage. Int Angiol 1993;12:355359.

6. Boffa MC, Karochkine M, Berard M. Plasma thrombomodulin as a marker of endothelium damage. J Rev Fr Hematol 1991;33:529-530.

7. Naruse M, Kawana M, Hifumin S, Demura H. Plasma immunoreactive endothelin, but not thrombomodulin, is increased in patients with essential

hypertension and ischaemic heart disease. J Cardiol Pharmacol 1991;17:S471474.

8. Seigneur M, Dufourg P, Conri C, Boisseau M, Levels of plasma thrombomodulin are increased in atheromatous arterial disease. Thromb Res 1993;71:423-431.

9. Butthep P, Bunyaratvei A, Funahara Y, Kitaguchi H, Fucharoen S, Sato S, Bhamarapravati N. Alterations in vascular endothelial cell-related plasma proteins in thalassaemic patients and their correlation with clinical symptoms. Thromb Haemost 1995;74:1045-1049.

10. Papp AC, Hatzakis H, Bracey A, Wu KK. ARIC Hemostasis Study, development of blood collection and processing system suitable for multicenter hemostatic study. Thromb Haemost 1989;61:15-19.